Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive Investors that the biotech company will be producing its first series of clinical grade exosome products, used for skincare and hair growth, by the second half of 2019.
Dr. Jin adds that the New Jersey-based company is collaborating with the Massachusetts Institute of Technology to develop an AI-enhanced protein design technology, which will allow the company to innovate in new cell therapy techniques.
Source: Proactive Investors
